At what enterprise value was NEURAXPHARM acquired in 2020?

During the acquisition of NEURAXPHARM by PERMIRA in 2020, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of NEURAXPHARM when it was acquired by PERMIRA?

The estimated EV/EBITDA multiple for NEURAXPHARM is in the range of Above 20x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was NEURAXPHARM acquired by PERMIRA?

NEURAXPHARM was acquired by PERMIRA in 2020.

What was the revenue of NEURAXPHARM at the time of the deal?

The revenue of NEURAXPHARM at the time of the deal is estimated to be in the range of 250M - 500M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of NEURAXPHARM during the acquisition?

NEURAXPHARM's EBITDA is estimated to be in the range of 50M - 100M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the NEURAXPHARM acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the NEURAXPHARM deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.permira.com/news-and-insights/announcements/permira-funds-to-acquire-leading-european-cns-specialty-pharmaceutical-company-neuraxpharm

← DATABASE

Home Database Healthcare & PharmaNEURAXPHARM

09/2020

NEURAXPHARM acquired by PERMIRA

GERMANY Life Sciences / Pharma & Biotech / Generics / Labs EV 1b - 4b EUR

Context

Permira acquired Neuraxpharm from Apax Partners, following a competitive auction process. The transaction was structured to support the company's transition from a regional player to a pan-European leader. Under Permira's ownership, the management team led by CEO Dr. Dierks remained in place to execute a high-velocity buy-and-build strategy. The deal was financed through a combination of equity and a significant leveraged loan package, aiming to capitalize on the resilient and growing market for CNS treatments. Following the acquisition, Permira supported the group in expanding its geographical footprint across Europe and into international markets like Brazil and Australia, while simultaneously investing in a robust pipeline of high-tech and innovative CNS molecules.

NEURAXPHARM, which reported an EBITDA margin of in 2020, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of Central Nervous System (CNS) disorders. It develops and commercializes value-added medicines and consumer healthcare products for chronic conditions such as Epilepsy, Parkinson s, Alzheimer s, Depression, and Psychosis. It holds leading positions in Germany and Spain and covers over 115 different CNS molecules.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2020

2019

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
10/2020	SULZER	HASELMEIER	SWITZERLAND	Medical Consumables
10/2020	ARDIAN	H2 PHARMA	FRANCE	CDMO
09/2020	EQT PARTNERS	SCHÜLKE	GERMANY	Medical Consumables
09/2020	PATRICIA INDUSTRIES	ADVANCED INSTRUMENTS	UNITED STATES	Diagnostic Equipment
06/2020	AVISTA CAPITAL PARTNERS	VISION HEALTHCARE	BELGIUM	Nutrition & Dietary Supplements
04/2020	WARBURG PINCUS	POLYPLUS	FRANCE	R&D Biotech
04/2020	AMERICAN SECURITIES	PARAGON MEDICAL	UNITED STATES	Medical Devices
04/2020	ROYAL DSM	GLYCOM	DENMARK	Nutrition & Dietary Supplements
03/2020	LBO FRANCE	DUTSCHER	FRANCE	Medical Consumables
02/2020	TETHYS INVEST / PSP INVESTMENTS / MITSUI & CO	CEVA SANTE ANIMALE	FRANCE	Animal Health

REFERENCES

Valuation range: EV 1b - 4b EUR

Revenue range: 250M - 500M EUR

EBITDA range: 50M - 100M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of NEURAXPHARM by PERMIRA are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Target: neuraxpharm

Acquirer: permira